Movement Alert｜Iovance Biotherapeutics, Inc. Intraday Decline 8.11%, Sell-the-news pressure persisted after mNSCLC data update

Market Focus10-30 22:02

On October 30, Iovance Biotherapeutics, Inc. fell 8.11% in Regular Trading, trading at $8.35 per share, with turnover of $58.35 million.

The latest market-moving development points to continued sell-the-news pressure after the company’s October 29 webcast on positive TIL therapy data in metastatic non-small cell lung cancer and its broader precision medicine strategy.

Earlier trading around that update was initially strong across after-hours, overnight and pre-market activity, but the stock later reversed sharply as gains were taken back. Background remains fundamentally constructive: the company previously raised full-year revenue guidance to $410 million-$420 million from $350 million-$370 million, citing strong demand for Amtagvi and Proleukin, while consensus ahead of the November 5 earnings release calls for about $116 million in quarterly revenue, up 59.56% year over year, and adjusted EPS of negative $0.09, versus negative $0.11 in the prior quarter.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment